This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hull, M. A. Articles by Hawcroft, G. Search for Related Content PubMed PubMed Citation Articles by Hull, M. A. Articles by Hawcroft, G. Related Collections Therapeutics and Targets Therapeutics and Targets: Identification, Validation, and Markers Epidemiology and Prevention: Chemoprevention

Minireview

Prostaglandin EP receptors: Targets for treatment and prevention of colorectal cancer?

Molecular Medicine Unit, University of Leeds, St. James's University Hospital, Leeds, United Kingdom

Request for reprints: Mark A. Hull, Molecular Medicine Unit, University of Leeds, Clinical Sciences Building, St. James's University Hospital, Leeds LS9 7TF, United Kingdom. Phone: 44-113-206-5251; Fax: 44-113-242-9722. E-mail: M.A.Hull{at}leeds.ac.uk

The importance of the prostaglandin (PG) synthesis pathway, particularly the rate-limiting enzymatic step catalyzed by cyclooxygenase, to colorectal carcinogenesis and development of novel anticolorectal cancer therapy is well established. The predominant PG species in benign and malignant colorectal tumors is PGE₂. PGE₂ acts via four EP receptors termed EP1 to EP4. Recently, EP receptors have been identified as potential targets for treatment and/or prevention of colorectal cancer. This review summarizes existing knowledge of the expression and function of the EP receptor subtypes in human and rodent intestine during tumorigenic progression and describes the current literature on targeting EP receptor signaling during intestinal tumorigenesis.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 3/ 3/04; revised 5/12/04; accepted 5/26/04.

This article has been cited by other articles:

				G. Natarajan, S. Ramalingam, I. Ramachandran, R. May, L. Queimado, C. W. Houchen, and S. Anant CUGBP2 downregulation by prostaglandin E2 protects colon cancer cells from radiation-induced mitotic catastrophe Am J Physiol Gastrointest Liver Physiol, May 1, 2008; 294(5): G1235 - G1244. [Abstract] [Full Text] [PDF]

				S.-Y. Kim, M. Seo, Y. Kim, Y.-I. Lee, J.-M. Oh, E.-A. Cho, J.-S. Kang, and Y.-S. Juhnn Stimulatory Heterotrimeric GTP-binding Protein Inhibits Hydrogen Peroxide-induced Apoptosis by Repressing BAK Induction in SH-SY5Y Human Neuroblastoma Cells J. Biol. Chem., January 18, 2008; 283(3): 1350 - 1361. [Abstract] [Full Text] [PDF]

				K. J. Sales, S. C. Boddy, A. R. W. Williams, R. A. Anderson, and H. N. Jabbour F-Prostanoid Receptor Regulation of Fibroblast Growth Factor 2 Signaling in Endometrial Adenocarcinoma Cells Endocrinology, August 1, 2007; 148(8): 3635 - 3644. [Abstract] [Full Text] [PDF]

				C. R. J. Kennedy, H. Xiong, S. Rahal, J. Vanderluit, R. S. Slack, Y. Zhang, Y. Guan, M. D. Breyer, and R. L. Hebert Urine concentrating defect in prostaglandin EP1-deficient mice Am J Physiol Renal Physiol, February 1, 2007; 292(2): F868 - F875. [Abstract] [Full Text] [PDF]

				J. Li, K. L. O'Connor, X. Cheng, F. C. Mei, T. Uchida, C. M. Townsend Jr, and B. M. Evers Cyclic Adenosine 5'-Monophosphate-Stimulated Neurotensin Secretion Is Mediated through Rap1 Downstream of both Epac and Protein Kinase A Signaling Pathways Mol. Endocrinol., January 1, 2007; 21(1): 159 - 171. [Abstract] [Full Text] [PDF]

				M. D. Castellone, H. Teramoto, and J. S. Gutkind Cyclooxygenase-2 and Colorectal Cancer Chemoprevention: The {beta}-Catenin Connection Cancer Res., December 1, 2006; 66(23): 11085 - 11088. [Abstract] [Full Text] [PDF]

				L. Yang, Y. Huang, R. Porta, K. Yanagisawa, A. Gonzalez, E. Segi, D. H. Johnson, S. Narumiya, and D. P. Carbone Host and Direct Antitumor Effects and Profound Reduction in Tumor Metastasis with Selective EP4 Receptor Antagonism Cancer Res., October 1, 2006; 66(19): 9665 - 9672. [Abstract] [Full Text] [PDF]

				S. D. Chell, I. R. Witherden, R. R. Dobson, M. Moorghen, A. A. Herman, D. Qualtrough, A. C. Williams, and C. Paraskeva Increased EP4 Receptor Expression in Colorectal Cancer Progression Promotes Cell Growth and Anchorage Independence. Cancer Res., March 15, 2006; 66(6): 3106 - 3113. [Abstract] [Full Text] [PDF]

				S. Han, J. D. Ritzenthaler, B. Wingerd, and J. Roman Activation of Peroxisome Proliferator-activated Receptor {beta}/{delta} (PPAR{beta}/{delta}) Increases the Expression of Prostaglandin E2 Receptor Subtype EP4: THE ROLES OF PHOSPHATIDYLINOSITOL 3-KINASE AND CCAAT/ENHANCER-BINDING PROTEIN {beta} J. Biol. Chem., September 30, 2005; 280(39): 33240 - 33249. [Abstract] [Full Text] [PDF]

				S.-H. Chang, Y. Ai, R. M. Breyer, T. F. Lane, and T. Hla The Prostaglandin E2 Receptor EP2 Is Required for Cyclooxygenase 2-Mediated Mammary Hyperplasia Cancer Res., June 1, 2005; 65(11): 4496 - 4499. [Abstract] [Full Text] [PDF]